CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
616-630 of 925
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
MinuteCE®First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
MinuteCE®Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
- advertisement
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
CME/CEAdvances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
- advertisement
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®Overcoming EGFR Resistance With HER3-Directed ADCs
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
